168 related articles for article (PubMed ID: 22869928)
1. Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.
Zhou Q; Lv H; Mazloom AR; Xu H; Ma'ayan A; Gallo JM
J Pharmacol Exp Ther; 2012 Nov; 343(2):509-19. PubMed ID: 22869928
[TBL] [Abstract][Full Text] [Related]
2. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Zhou Q; Guo P; Gallo JM
Clin Cancer Res; 2008 Mar; 14(5):1540-9. PubMed ID: 18316579
[TBL] [Abstract][Full Text] [Related]
3. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M
Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987
[TBL] [Abstract][Full Text] [Related]
4. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
[TBL] [Abstract][Full Text] [Related]
5. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Zhou Q; Gallo JM
Neuro Oncol; 2009 Jun; 11(3):301-10. PubMed ID: 18971416
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
12. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
13. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Giuliano S; Cormerais Y; Dufies M; Grépin R; Colosetti P; Belaid A; Parola J; Martin A; Lacas-Gervais S; Mazure NM; Benhida R; Auberger P; Mograbi B; Pagès G
Autophagy; 2015; 11(10):1891-904. PubMed ID: 26312386
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
15. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.
Gaustad JV; Simonsen TG; Leinaas MN; Rofstad EK
BMC Cancer; 2012 Sep; 12():388. PubMed ID: 22947392
[TBL] [Abstract][Full Text] [Related]
17. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
18. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
[TBL] [Abstract][Full Text] [Related]
20. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
Sablin MP; Dreyer C; Colichi C; Bouattour M; Delbaldo C; Faivre S; Raymond E
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1005-15. PubMed ID: 20636223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
